RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026
RenovoRx, Inc. (RNXT)
Company Research
Source: GlobeNewswire
MOUNTAIN VIEW, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will participate in the AlphaNorth Capital Event. The conference will be held from January 16-18, 2026. Mr. Bagai will share an update on RenovoRx’s commercial progress, fueled by increasing demand for RenovoCath® as a standalone targeted drug-delivery device. Adoption is growing among both new and returning customers, including top cancer centers, highlighting the expanding need for localized, targeted treatment made possible through RenovoRx’s proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform. He will also discuss RenovoRx’s ongoing Phase III TIGeR-PaC clinical trial evaluating intra-arterial gemcitabine (IAG) delivered via RenovoCath in pati
Show less
Read more
Impact Snapshot
Event Time:
RNXT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNXT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNXT alerts
High impacting RenovoRx, Inc. news events
Weekly update
A roundup of the hottest topics
RNXT
News
- RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026GlobeNewswire
- RenovoRx (NASDAQ:RNXT) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026 [Yahoo! Finance]Yahoo! Finance
- RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026GlobeNewswire
- RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9thGlobeNewswire
RNXT
Earnings
- 5/15/25 - In-Line
RNXT
Sec Filings
- 1/5/26 - Form 4
- 1/2/26 - Form 4
- 1/2/26 - Form 8-K
- RNXT's page on the SEC website